

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Bepirovirsen nucleoside or nucleotide analogues for treating chronic hepatitis B [ID6608]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

<p>1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?</p>
<p>One stakeholder noted that hepatitis B disproportionately affects men who have sex with men.</p> <p>One stakeholder noted that hepatitis B disproportionately affects people with recorded diagnosis of HIV, hepatitis C virus, or syphilis.</p> <p>Multiple stakeholders highlighted that hepatitis B disproportionately affects socially vulnerable people, including migrants, communities experiencing socioeconomic deprivation, people who inject drugs, and people living in prisons or other detention settings.</p>
<p>2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?</p>
<p>Sexual orientation and disability are protected characteristics under equalities legislation. The committee will consider the issues during development of the guidance. The committee will need to consider any equality issues related to eligibility criteria in its decision-making.</p>
<p>3. Has any change to the draft scope been agreed to highlight potential equality issues?</p>

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): Lorna Dunning

Date: 27/05/2026